Exceeding its cut-off value before therapy was associated with more severe CTEPH before therapy (higher mPAP, PVR, NT-pro-BNP and troponin and lower TAPSE) and an increased risk of death. The gene discussed is NPPB; the disease is chronic thromboembolic pulmonary hypertension.